Antiviral therapy of acute herpes zoster in older patients

Drugs and Aging

Volumn 8, Issue 2, 1996, Pages 97-112

  Herne, Kathleen ^a   Cirelli, Richard ^a   Lee, Patricia ^a   Tyring, Stephen K ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CORTICOSTEROID; CYTARABINE; FAMCICLOVIR; IDOXURIDINE; NETIVUDINE; PENCICLOVIR; PREDNISOLONE; PRODRUG; SORIVUDINE; TRIAMCINOLONE; VALACICLOVIR; VARICELLA ZOSTER VACCINE; VIDARABINE;

ADULT; AGED; BONE MARROW SUPPRESSION; CHICKENPOX; CLINICAL TRIAL; DIARRHEA; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG MECHANISM; HERPES ZOSTER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MORBIDITY; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; REVIEW; SKIN DEFECT;

EID: 0030052215     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608020-00004     Document Type: Review

References (89)

1. Burgoon CF, Burgoon JS, Baldridge GD. The natural history of herpes zoster. JAMA 1957; 164: 265-9
2. Hope-Simpson RE. The nature of herpes zoster - a long-term study and a new hypothesis. Proc R Soc Lond B 1965; 58: 9-20
3. Ragozzino MW, Melton LF, Kurland LT. Population-based study of herpes zoster and its sequelae. Medicine 1982; 61: 310-6
4. Ostrove JM, Inchauspe G. Varicella-zoster virus infections: biology, natural history treatment and prevention. Ann Intern Med 1988; 108 (2): 221-37
5. Dolin R, Reichman RC, Mazur MH, et al. Herpes zoster varicella infections in immunosuppressed patients. Ann Intern Med 1978; 89: 375-88
6. Gnann JW, Whitley RJ. Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect 1991; 18 Suppl. A: 317-29
7. Rogers RS, Tindall JP. Geriatric herpes zoster. J Am Geriatr Soc 1971; 19 (6): 495-503
8. Gilden DM, Dueland AN, Cohrs R, et al. Preherpetic neuralgia. Neurology 199; 41: 1215-8
9. Lewis GW. Zoster sine herpete. BMJ 1958; 2: 418-21
10. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Ann Neurol 1986; 20: 651-64
11. de Moragas JM, Kierland RR. The outcome of patients with herpes zoster. Arch Dermatol 1957; 75: 193-6
12. Culbertson WW, Blumenkranz MS, Pepose JS, et al. Varicella-zoster virus is a cause of the acute retinal necrosis syndrome. Ophthalmology 1986; 93: 559-62
13. Tyring SK. The natural history of varicella zoster virus. Semin Dermatol 1992; 11 (3): 211-7
14. Mazur MH, Dolin R. Herpes zoster at the NIH: a twenty-year history. Am J Med 1978; 65: 738-44
15. Merselis JG, Kaye D, Hook EW. Disseminated herpes zoster. Arch Intern Med 1964; 113: 679-86
16. Wood MJ. Current experience with antiviral therapy for acute herpes zoster. Ann Neurol 1994; 35: 565-8
17. Strommen GL, Pucino F, Tight RR, et al. Human infection with herpes zoster: etiology, pathophysiology, diagnosis, clinical course, and treatment. Pharmocotherapy 1988; 8 (1): 52-68
18. Juel-Jensen BE, MacCallum FO, MacKenzie AMR, et al. Treatment of zoster with idoxuridine dimethyl sulfoxide: results of two double-blind controlled trials. BMJ 1970; 4: 776-80
19. Dawber R. Idoxuridine in the treatment of herpes zoster: further evaluation of intermittent topical therapy. BMJ 1974; 2: 526-7
20. Wildenhoff KE, Insen J, Esmann V, et al. Treatment of herpes zoster with idoxuridine ointment including a multivariate analysis of signs and symptoms. Scand J Infect Dis 1979; 11: 1-9
21. Wildenhoff KE, Esmann V, Ipsen J, et al. Treatment of trigeminal and thoracic zoster with idoxuridine. Scan J Infect Dis 1981; 13: 257-62
22. Loeser JD. Herpes zoster and post herpetic neuralgia. Pain 1986; 25: 149-64
23. Zaky A, Betts RF, Douglas RG, et al. Double-blind study of cytarabine in localized herpes zoster [abstract]. Clin Res 1974; 22: 458A
24. Stevens DA, Jordan GW, Waddel TF, et al. Adverse effects of cytosine arabinoside on disseminated herpes zoster in a controlled trial. N Engl J Med 173; 289: 873-977
25. Betts RF, Zaky DA, Douglas Jr RG, et al. Ineffectiveness of subcutaneous cytosine arabinoside in localized herpes zoster. Ann Intern Med 1975; 82: 778-83
26. Sasadeusz JJ, Sachs SL. Systemic antivirals in herpesvirus infections. Dermatol Ther 1993; 11 (1): 171-85
27. Whitley RJ, Chien LT, Dolin R, et al. Adenine arabinoside therapy of herpes zoster in the immunosuppressed. N Engl J Med 1976; 294: 1193-9
28. Whitley RJ, Soong ST, Dolin R, et al. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med 1982; 307 (16): 971-5
29. Shepp DH, Dandicker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients: a randomized comparison of aciclovir and vidarabine. N Engl J Med 1986; 314 (4): 208-12
30. Vilde JL, Bricaire F, Leport C, et al. Comparative trial of acyclovir and vidarabine in disseminated varicella-zoster virus infections in immunosuppressed patients. J Med Virol 1986; 20: 127-34
31. Whitley RJ, Gnann JW, Hinthorn D, et al. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. J Infect Dis 1992; 165: 450-5
32. Elion GB, Furman PA, Fyfe JH, et al. Selectivity of action of an antiherpetic agent, 9-[(2-hydroxyethoxy)methyl] guanine. Proc Natl Acad Sci USA 1977; 74 (4): 5716-20
33. Derse D, Cheng Y-C, Furman PA, et al. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl) guanine triphosphate. J Biol Chem 1981; 256 (11): 11447-51
34. McGuirt PV, Furman PA. Acyclovir inhibition of DNA chain elongation in herpes simplex virus-infected cells. Am J Med 1982; 73 Suppl.: 67-71
35. Straus SE. Shingles: sorrows, salves, and solutions. JAMA 1994; 269 (14): 1836-9
36. Cirelli R, Memar O, Herne K, et al. Therapy and prophylaxis of viral diseases with cutaneous manifestations. Can J Dermatol 1995; 7: 795-804
37. Purifoy DJM, Beauchamp LU, deMiranda P, et al. Review of research leading to new anti-herpes virus agents in clinical development: valacyclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol 1993; Suppl. 1: 139-45
38. Gelb LD. Varicella zoster virus infections. Current Opin Infect Dis 1989; 2: 256-61
39. Serupere A, Sauz GF, Sevant L, et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992; 10: 495-8
40. Goldberg LH, Kaufman R, Kurtz TO, et al. for the Acyclovir Study Group. Long-term suppression of recurrent genital herpes with acyclovir: a 5-year benchmark. Arch Dermatol 1993; 129: 582-7
41. Peterslund NA, Seyer-Hausen K, Ipsen J, et al. Acyclovir in herpes zoster. Lancet 1981; ii: 827-30
42. Bean B, Braun C, Balfour Jr HH. Acyclovir therapy for acute herpes zoster. Lancet 1982; ii: 118-21
43. van den Broek PJ, van der Meer JWM, Mulder JD, et al. Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study. Infection 1984; 12: 338-41
44. Juel-Jensen BF, Khan JA, Pasvol G. High dose intravenous acyclovir in the treatment of zoster: a double-blind placebo-controlled trial. J Infect 1983; 6 Suppl. 1: 31-6
45. McGill J, McDonald DR, Fall C, et al. Intravenous acyclovir in acute herpes zoster infection. J Infect 1983; 6: 157-61
46. Balfour Jr HH, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308: 1448-53
47. Peterslund NA, Esmann J, Ipsen K, et al. Oral and intravenous acyclovir are equally effective in herpes zoster. J Antimicrob Chemother 1985; 14: 185-9
48. McKendrick MW, Care C, Burke C, et al. Oral acyclovir in herpes zoster. J Antimicrob Chemother 1984; 15: 661-5
49. Wassilew SW, Reimlinger S, Nasemann T, et al. Oral acyclovir for herpes zoster: a double-blind controlled trial in normal subjects. Br J Dermatol 1987; 117: 495-501
50. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986; 93: 763-70
51. Huff JC, Bean B, Balfour Jr HH, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85 Suppl. 2A: 84-9
52. Wood MJ, Ogan PH, McKendrick MW, et al. Efficacy of oral acyclovir in the treatment of acute herpes zoster. Am J Med 1989; 85 Suppl. 2A: 79-83
53. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93-5
54. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991; 10: 177-82
55. Huff JC, Drucker JL, Clemmer A, et al. Efficacy of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993; Suppl. 1: 93-6
56. Crooks RT, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect 1991; Suppl. 78: 62-8
57. Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896-900
58. Elliott FA. Treatment of herpes zoster with high doses of prednisone. Lancet 1964; ii: 610-1
59. Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970; 211 (10): 1681-3
60. Keezkes K, Basheer AM. Do corticosteroids prevent postherpetic neuralgia? Br J Dermatol 1989; 102: 551-5
61. Clemmensen OJ, Anderson KE. ACTH versus prednisone and placebo in herpes zoster treatment. Clin Exp Dermatol 1984; 9: 557-63
62. Esmann V, Geil JP, Kroon S, et al. Prednisolone does not prevent post herpetic neuralgia. Lancet 1987; ii: 126-9
63. Post B, Philbrick JT. Do corticosteroids prevent postherpetic neuralgia? A review of the evidence. J Am Acad Dermatol 1988; 18: 605-10
64. Merselis JG, Kaye D, Hook EW. Disseminated herpes zoster. Arch Intern Med 1964; 113: 679-86
65. Whitley RJ, Weiss H, Gnann J, et al. The efficacy of steroids and acyclovir therapy of herpes zoster in the elderly [abstract]. Antiviral Res 1995; 26: A303
66. Bacon T. Famciclovir: potency, predictability, and persistence [abstract]. Third Congress of the European Academy of Dermatology and Venereology; 1993 Sep 26-30; Copenhagen, Denmark, 6-7
67. Earnshaw DL, Vere Hodge RA. Effective inhibition of herpesvirus DNA synthesis by (S)-penciclovir-triphosphate [abstrac 1707]. American Society for Microbiology, 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy 1992 Oct 11-14; Anaheim
68. Pratt SK, Beerahee M, Pere MA, et al. The pharmacokinetics of penciclovir following oral administration of 500mg famciclovir to patients with uncomplicated herpes zoster [poster]. Third Congress of the European Academy of Dermatology and Venereology; 1993 Sep 26-30; Copenhagen, Denmark, 18-9
69. Vere Hodge RA. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 1993; 4 (2): 67-84
70. Boyd MR, Bacon TH, Sutton D, et al. Antiherpesvirus activity of 9- (4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother 1987; 31: 1238-42
71. Pue MA, Benet LZ. Pharmacokinetics of famciclovir in man. Antiviral Chem Chemother 1993; 4 Suppl. 1: 47-55
72. Pratt SK, Fairless AJ, Peu MA, et al. The haemodialysis of penciclovir [abstract 1286]. Sixth International Congress for Infectious Diseases; 1994 Apr 26-30; Prague, Czech Republic
73. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994; 38 (10): 2454-7
74. Tyring SK, Nahlik J, Cunningham A, et al. A double-blind, randomized, placebo-controlled, parallel group study of oral famciclovir for the treatment of uncomplicated herpes zoster. Ann Intern Med 1995; 123: 89-96
75. Degreef H, Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4: 241-6
76. Jacobson MA. Valacyclovir (BW256U87): the 1-valyl ester of acyclovir. J Med Virol 1993; Suppl. 1: 150-3
77. Burnette TC, de Miranda P. Metabolic disposition of the acyclovir prodrug valacyclovir in the rat. Drug Metab Dispos 1994; 22 (1): 60-4
78. de Miranda P, Burnette TC. Metabolic fate and pharmacokinetics of the acyclovir prodrug valacyclovir in cynomolgus monkeys. Drug Metab Dispos 1994; 22 (1): 55-9
79. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir prodrug valacyclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993; 54 (6): 595-605
80. Feinberg J, Gallant J, Weller S, et al. A phase I evaluation of 256U87, an acyclovir prodrug, in HIV infected patients [abstract No. POB3885]. Eighth International Conference on AIDS; 1992 Jul 19-24; Amsterdam
81. Darby G. Acyclovir - and beyond. J Int Med Res 1994; 22 Suppl. 1: 33A-42A
82. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39: 1546-53
83. Beutner K. Antivirals in the treatment of pain. J Geriatr Dermatol 1994; 2 Suppl. 6: 23A-8A
84. Gnann JW. New antivirals with activity against varicella-zoster virus. Ann Neurol 1994; 35 Suppl.: S69-72
85. Crooks RJ, Peck RW, Wood MJ. An open study to investigate the clinical potential, pharmacokinetics, and safety of 882C in patients with herpes zoster [abstract]. Antiviral Res 1993; 20 Suppl. 1: 144
86. Fiddian AP, and the International Zoster Study Group. A randomized controlled trial of Zovirax (acyclovir, ACV) versus netivudine for the treatment of herpes zoster [abstract]. Antiviral Res 1995; 26: A297
87. Wallace MR, Sawyer MH, Chamberlin CK, et al. BV-ara-U for the treatment of adult varicella [abstract 25]. The Second International Conference on the Varicella Zoster Virus; 1994 Jul; Paris
88. Boag F, Bodsworth N, Burdge D, et al. The safety and efficacy of sorivudine (BV-ara-u) for the treatment of zoster in HIV-infected adults: results of a multinational comparative trial [abstract 26]. The Second International Conference on the Varicella Zoster Virus; 1994 Jul; Paris
89. Hardy I, Gershon AA, Steinberg SP, et al. The incidence of zoster after immunization with live attenuated varicella vaccine. N Engl J Med 1991; 325: 1545-50